Literature DB >> 24834659

[Human immunodeficiency virus type 1 subtypes in Djibouti].

A Elmi Abar, A Jlizi, H Youssouf Darar, M Ben Nasr, S Abid, M Ali Ben Hadj Kacem, A Slim.   

Abstract

The authors had for aim to study the distribution of HIV-1 subtypes in a cohort of HIV positive patients in the hospital General Peltier of Djibouti. An epidemiological study was made on 40 HIV-1 positive patients followed up in the Infectious Diseases Department over three months. All patients sample were subtyped by genotyping. Thirty-five patients (15 men and 20 women) were found infected by an HIV-1 strain belonging to the M group. Genotyping revealed that - 66% of samples were infected with subtype C, 20% with CRF02_AG, 8.5% with B, 2.9% with CRF02_AG/C and 2.9% with K/C. In fact, Subtype C prevalence has been described in the Horn of Africa and a similar prevalence was previously reported in Djibouti. However our study describes the subtype B in Djibouti for the first time. It is the predominant subtype in the Western world. The detection of CRF02_AG strains indicates that they are still circulating in Djibouti, the only country in East Africa in which this recombinant virus was found. CRF02_AG recombinant isolates were primarily described in West and Central Africa. The presence of this viral heterogeneity, probably coming from the mixing of populations in Djibouti, which is an essential economic and geographical crossroads, incites us to vigilance in the surveillance of this infection.

Entities:  

Mesh:

Year:  2012        PMID: 24834659

Source DB:  PubMed          Journal:  Arch Inst Pasteur Tunis        ISSN: 0020-2509


  1 in total

1.  Genetic Diversity and Acquired Drug Resistance Mutations Detected by Deep Sequencing in Virologic Failures among Antiretroviral Treatment Experienced Human Immunodeficiency Virus-1 Patients in a Pastoralist Region of Ethiopia.

Authors:  Erdaw Tachbele; Samuel Kyobe; Fred Ashaba Katabazi; Edgar Kigozi; Savannah Mwesigwa; Moses Joloba; Alebachew Messele; Wondwossen Amogne; Mengistu Legesse; Rembert Pieper; Gobena Ameni
Journal:  Infect Drug Resist       Date:  2021-11-18       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.